1
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
----------------------------------
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) May 8, 2000
-----------
EPOCH PHARMACEUTICALS, INC.
- --------------------------------------------------------------------------------
(Exact name of Registrant as specified in charter)
Delaware 0-22170 91-1311592
- --------------------------------------------------------------------------------
(State or other jurisdiction (Commission (I.R.S. Employer
of incorporation) File Number) Identification No.)
12277 134th Court NE, Suite 110,
Redmond, Washington 98052
- --------------------------------------------------------------------------------
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code (425) 821-7535
--------------
Not Applicable
- --------------------------------------------------------------------------------
(Former name or former address, if changed, since last report.)
Page 1 of 6 Pages
Exhibit Index is on Page 4
2
ITEM 5. OTHER EVENTS.
On May 8, 2000, Epoch Pharmaceuticals, Inc., a Delaware corporation, doing
business as Epoch Biosciences (the "Company"), issued a press release announcing
that it had been approved for listing on the Nasdaq National Market. A copy of
the press release is attached as Exhibit 99.1 and incorporated herein by this
reference.
Exhibit
Number
-------
99.1 Press Release, dated May 8, 2000, entitled "Epoch Biosciences
Approved for Nasdaq National Market"
2
3
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this Report to be signed on its behalf by the
undersigned thereunto duly authorized.
EPOCH PHARMACEUTICALS, INC.
Date: May 8, 2000 By: /s/ Sanford S. Zweifach
--------------------------------
Sanford S. Zweifach
President and Chief Financial
Officer
4
EXHIBIT INDEX
The following exhibits are attached hereto and incorporated herein by
reference:
Exhibit Sequentially
Number Numbered Page
------- -------------
99.1 Press Release, dated May 8, 2000, entitled 5
"Epoch Biosciences Approved for Nasdaq
National Market"